{"entity":{"id":"nct07185880","kind":"trial","name":"A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients","aka":["STAR-GBM"],"tldr":"A phase 1/2 trial of MT-125 in glioma & glioblastoma, run by Myosin Therapeutics Inc., now recruiting.","summary":"A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients is a phase 1/2 interventional study registered as NCT07185880 by Myosin Therapeutics Inc., with 36 participants planned, started 2026-04-01 and due to reach its primary completion in 2026-10-31. Interventions recorded: MT-125.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07185880","url":"https://clinicaltrials.gov/study/NCT07185880"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07185880","phase":"1/2","setting":"A Phase 1/2 Single-Arm Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of MT-125 Monotherapy With Radiation in Newly Diagnosed Glioblastoma","sponsor":"Myosin Therapeutics Inc.","participation":[{"nct":"NCT07185880","source":"https://clinicaltrials.gov/study/NCT07185880","fetchedAt":"2026-10-07T16:55:32.313Z","studySha256":"c64ff1f6bfd73eda3164cb03dfcdda75cc6555ed2b2c01a0568a56795267719f","overallStatus":"RECRUITING","lastUpdatePosted":"2026-04-14","leadSponsor":"Myosin Therapeutics Inc.","collaboratorCount":2,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":36,"enrolmentType":"ESTIMATED","siteCount":3,"recruitingSiteCount":3,"countries":["United States"]}],"started":"2026-04-01","startedType":"actual","enrolled":36,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07185880/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}]}}